NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|November 1, 2023

Available Treatment Options for Later Lines of Therapy in Patients With RRMM

Author(s)Rafael Fonseca, MD

Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.

Episodes in this series

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 1 Case Presentation: A 66-Year-Old Man with Relapsed/Refractory Multiple Myeloma (RRMM)

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 2 Reviewing Treatment Decisions for a 66-Year-Old Man With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 3 Available Treatment Options for Later Lines of Therapy in Patients With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 4 Results and Key Takeaways From the TriMM-2 Study in Patients With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 5 Analysis of Infections and Humoral Immunity in Patients With RRMM Treated With Talquetamab Monotherapy in MonumenTAL-1

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 6 Optimal Sequencing in Patients With RRMM Previously Treated With a BCMA-Targeted Therapy

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 7 Novel Treatments and Targets Under Investigation for Patients With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 8 Clinical Pearls for Community Oncologists Treating Patients With RRMM

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma

ByJonah Feldman

January 29th 2026

Comparing Teclistamab Trial Designs for Early Relapsed Multiple Myeloma

ByRoberto Mina, MD

January 29th 2026

FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma

ByJonah Feldman

January 27th 2026

FDA Grants Fast Track Designation to IBI3003 for R/R Multiple Myeloma

ByJonah Feldman

January 27th 2026

Modern Relapsed Myeloma Population Is Addressed in MajesTEC-9

ByRoberto Mina, MD

January 23rd 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

The Targeted Pulse: New Standards in Myeloma, Melanoma, and More

Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC

Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers

NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC